Doseloop Beta

Memantine

medication Under review

An NMDA receptor antagonist often used for cognitive enhancement and neuroprotection.

Research summary

AI-Generated Content: This summary was created by AI and may contain errors. Always verify with peer-reviewed sources.

Most human research on memantine has been conducted in patients with Alzheimer’s disease or other dementias, where randomized controlled trials and meta-analyses show modest benefits on cognition and global function, along with a safety profile generally comparable to placebo at therapeutic doses. These data suggest that partial NMDA receptor blockade can produce clinically meaningful effects on cognition and may reduce excitotoxic neuronal injury in vulnerable populations. In contrast, there is very limited controlled research in truly healthy human subjects. Early-phase pharmacokinetic and safety studies in healthy volunteers indicate that memantine is orally bioavailable, crosses the blood–brain barrier, and is generally well tolerated at therapeutic doses, but they do not demonstrate clear cognitive enhancement. Ongoing or planned trials are exploring its use for prevention of Alzheimer’s disease in at‑risk but not yet demented individuals, which may provide more insight into neuroprotective effects in relatively healthy adults. At present, there is no strong human evidence that memantine improves memory, focus, or other cognitive domains in healthy people, and its use in this context remains experimental and off‑label.

Reported Benefits

Reported Side Effects

Research (6 studies)

Preliminary

The use of memantine for prevention of Alzheimer’s disease: a feasibility and safety study in cognitively normal older adults at risk

Alzheimer's & Dementia (Clinical Trial Registration NCT05063851) • 2022 • n=120

Manning CA, D'Abreu A, Fansler A, et al.

Meta-Analysis

Effect of long-term treatment with memantine on mortality in patients with dementia: a meta-analysis

Alzheimer's & Dementia: Translational Research & Clinical Interventions • 2019 • n=6263

Li L, Wu Z, Ma T, Liu Y

RCT

Pharmacokinetics and tolerability of memantine in healthy volunteers

Clinical Pharmacokinetics • 2006 • n=143

Periclou A, Ventura D, Rao N, Abramowitz W

RCT

Memantine pharmacokinetics in subjects with renal impairment and healthy volunteers

Clinical Pharmacokinetics • 2006 • n=28

Periclou A, Ventura D, Rao N, Abramowitz W

RCT

Phase I evaluation of the safety and tolerability of multiple ascending doses of memantine in healthy young adults

International Clinical Psychopharmacology • 1994 • n=18

Kornhuber J, Weller M, Schoppmeyer K, Riederer P

RCT

A randomized, double-blind, placebo-controlled trial of memantine in healthy volunteers: effects on cognition and subjective perception

Psychopharmacology • 1989 • n=24

Görtelmeyer R, Wollenweber R, Riederer P

Community updates

No updates yet for this supplement.

Be the first to share your experience!

At a glance

Users tracking 0
Linked studies 6
Researched benefits 2
Side effects noted 5